Platelets and cytokines in concert with endothelial activation in patients with peripheral arterial occlusive disease

Blood Coagulation and Fibrinolysis

Volumn 11, Issue 2, 2000, Pages 165-173

  Tsakiris, Dimitrios A ^a   Tschopl M ^b   Wolf, F ^a   Labs, K H ^b   Jager K A ^b   Marbet, G A ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b NONE

Author keywords

Arterial disease; CD40 ligand; Cell adhesion molecules; Endothelial activation; Oncostatin M; Platelet activation

Indexed keywords

CD63 ANTIGEN; CELL ADHESION MOLECULE; CYTOKINE; FIBRINOGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN GP 39; INTERCELLULAR ADHESION MOLECULE 1; ONCOSTATIN M; PADGEM PROTEIN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ANTIGEN EXPRESSION; ARTERY ENDOTHELIUM; ARTERY INTIMA PROLIFERATION; ARTICLE; BALLOON DILATATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FIBRINOGEN SYNTHESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RESTENOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE MEMBRANE;

EID: 0033993859     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200011020-00008     Document Type: Article

References (38)

1. 1. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-3561.
2. 2. Blann AD, Lip GY. The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications. Blood Coag Fibrinol 1998; 9: 297-306.
3. 3. Blann AD, McCollum CN. Increased soluble P-selectin in peripheral artery disease: a new marker for the progression of atherosclerosis [Letter]. Thromb Haemost 1998; 80: 1031-1032.
4. 4. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
5. 5. Dong ZM, Wagner DD. Leukocyte-endothelium adhesion molecules in atherosclerosis. J Lab Clin Med 1998; 132: 369-375.
6. 6. Tschopl M, Tsakiris DA, Marbet GA, Labs KH, Jager K. Role of hemostatic risk factors for restenosis in peripheral arterial occlusive disease after transluminal angioplasty. Arterioscler Thromb Vasc Biol 1997; 17: 3208-3214.
7. 7. Tsakiris DA, Tschopl M, Jager K, Haefeli WE, Wolf F, Marbet GA. Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease. Atherosclerosis 1999; 142: 193-200.
8. 8. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997; 96: 4219-4225.
9. 9. Blann AD, Seigneur M, Steiner M, Boisseau MR, McCollum CN. Circulating endothelial cell markers in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease. Eur J Clin Invest 1997; 27: 916-921.
10. 10. Blann AD, Devine C, Amiral J, McCollum CN. Soluble adhesion molecules, endothelial markers and atherosclerosis risk factors in abdominal aortic aneurysm: a comparison with claudicants and healthy controls. Blood Coag Fibrinol 1998; 9: 479-484.
11. 11. Wallace PM, MacMaster JF, Rillema JR, Peng J, Burstein SA, Shoyab M. Thrombocytopoietic properties of oncostatin M. Blood 1995; 86: 1310-1315.
12. 12. Wallace PM, MacMaster JF, Rillema JR, Rouleau KA, Hanson MB, Burstein SA, et al. In vivo properties of oncostatin M. Ann NY Acad Sci 1995; 762: 42-54.
13. 13. Vasse M, Paysant J, Soria J, Collet JP, Vannier JP, Soria C. Regulation of fibrinogen biosynthesis by cytokines, consequences on the vascular risk. Haemostasis 1996; 26 (suppl 4): 331-339.
14. 14. Vasse M, Paysant I, Soria J, Mirshahi SS, Vannier JP, Soria C. Down-regulation of fibrinogen biosynthesis by IL-4, IL-10 and IL-13. Br J Haematol 1996; 93: 955-961.
15. 15. Vasse M, Collet JP, Soria J, Mirshahi SS, Vannier JP, Soria C. Fibrinogen, a vascular risk factor: a simple marker or a real cause of vascular lesion? Thromb Res 1994; 75: 349-352.
16. 16. Grove RI, Eberhardt C, Abid S, Mazzucco C, Liu J, Kiener P, et al. Oncostatin M is a mitogen for rabbit vascular smooth muscle cells. Proc Natl Acad Sci USA 1993; 90: 823-827.
17. 17. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-594.
18. 18. Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997; 94: 1931-1936.
19. 19. Slupsky JR, Kalbas M, Willuweit A, Henn V, Kroczek RA, Muller-Berghaus G. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost 1998; 80: 1008-1014.
20. 20. Tschoepe D, Schultheiss HP, Kolarov P, Schwippert B, Dannehl K, Nieuwenhuis HK, et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993; 88: 37-42.
21. 21. Gawaz M, Neumann FJ, Schomig A. Evaluation of platelet membrane glycoproteins in coronary artery disease: consequences for diagnosis and therapy. Circulation 1999; 99: E1-E11.
22. 22. Gawaz M, Neumann FJ, Ott I, Schiessler A, Schomig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996; 93: 229-237.
23. 23. Scharf RE, Tomer A, Marzec UM, Teirstein PS, Ruggeri ZM, Harker LA. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection. Arterioscler Thromb 1992; 12: 1475-1487.
24. 24. Kolarov P, Tschoepe D, Nieuwenhuis HK, Gries FA, Strauer B, Schultheiss HP. PTCA: periprocedural platelet activation. Part II of the Duesseldorf PTCA platelet study (DPPS). Eur Heart J 1996; 17: 1216-1222.
25. 25. Cahill MR, Macey MG, Dawson JR, Newland AC. Platelet surface activation antigen expression at baseline and during elective angioplasty in patients with mild to moderate coronary artery disease. Blood Coag Fibrinol 1996; 7: 165-168.
26. 26. Zeller JA, Tschoepe D, Kessler C. Circulating platelets show increased activation in patients with acute cerebral ischemia. Thromb Haemost 1999; 81: 373-377.
27. 27. Jager KA, Phillips DJ, Martin RL, Hanson C, Roederer GO, Langlois YE, et al. Noninvasive mapping of lower limb arterial lesions. Ultrasound Med Biol 1985; 11: 515-521.
28. 28. Tsakiris DA, Haefeli WE, Linder L, Steiner B, Marbet GA. Platelet surface activation markers after DDAVP infusion in healthy subjects [Letter]. Thromb Haemost 1995; 74: 991-992.
29. 29. Steiner B, Trzeciak A, Pfenninger G, Kouns WC. Peptides derived from a sequence within beta 3 integrin bind to platelet alpha IIb beta 3 (GPIIb-IIIa) and inhibit ligand binding. J Biol Chem 1993; 268: 6870-6873.
30. 30. Lane P, Brocker T, Hubele S, Padovan E, Lanzavecchia A, McConnell F. Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation. J Exp Med 1993; 177: 1209-1213.
31. 31. Ferroni P, Pulcinelli FM, Lenti L, Gazzaniga PP. Is soluble P-selectin determination a more reliable marker of in vivo platelet activation than CD62P flow cytometry analysis? Thromb Haemost 1999; 81: 472-473.
32. 32. Yao L, Pan J, Setiadi H, Patel KD, McEver RP. Interleukin 4 or oncostatin M induces a prolonged increase in P-selectin mRNA and protein in human endothelial cells. J Exp Med 1996; 184: 81-92.
33. 33. Pourtau J, Soria C, Paysant J, Vannier JP, Vasse M. In-vitro effect of oncostatin M on the release by endothelial cells of von Willebrand factor, tissue-type plasminogen activator and plasminogen activator inhibitor-1 [In process citation]. Blood Coag Fibrinol 1998; 9: 609-615.
34. 34. Banerjee AK, Pearson J, Gilliland EL, Goss D, Lewis JD, Stirling Y, et al. A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Haemost 1992; 68: 261-263.
35. 35. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635-641.
36. 36. Montalescot G, Ankri A, Vicaut E, Drobinski G, Grosgogeat Y, Thomas D. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation 1995; 92: 31-38.
37. 37. Blann AD, Dobrotova M, Kubisz P, McCollum CN. von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb Haemost 1995; 74: 626-630.
38. 38. Dehmer GJ, Nichols TC, Bode AP, Liles D, Sigman J, Li S, et al. Assessment of platelet activation by coronary sinus blood sampling during balloon angioplasty and directional coronary atherectomy. Am J Cardiol 1997; 80: 871-877.